India's Neurotech Funding Wave: Temple, Mave and Sychedelic

A cluster of funding rounds in early 2026 made India's consumer and clinical neurotechnology sector suddenly hard to ignore. The largest was Temple, the venture from Eternal (Zomato) founder Deepinder Goyal, which raised a $54 million seed at a reported post-money valuation of around $190 million in February 2026 to build a temple-worn wearable that measures cerebral blood flow in real time. Weeks later, Mave Health raised a $2.1 million seed led by Blume Ventures for "Arc," a brain-stimulation headset priced at $495, and in May, Sychedelic, the pivot of the former EEG-headband startup Neuphony, raised $3.5 million for a closed-loop neuromodulation device in a headphone form factor.

Wearables and neuromodulation, not implants

What unites these companies is that none of them is putting anything inside the skull. India's neurotech wave is, for now, decisively non-invasive: EEG wearables that read brain activity from the scalp, and transcranial-stimulation devices that nudge it from outside. That is a deliberate market choice. Non-invasive devices clear a far lower regulatory and clinical bar than implants, can be sold directly to consumers, and address mass-market concerns, focus, stress, mood, sleep, rather than the narrow set of severe conditions that justify brain surgery.

Within that, a clinical-grade tier is forming. Sychedelic and Marbles Health, whose EASE device targets depression and anxiety, have pursued CDSCO medical-device clearance, which separates them from pure consumer gadgets. The broader landscape is real enough that trackers now count on the order of 13 Indian brain-computer-interface startups, placing India third globally by company count. Alongside the wearables sit BrainSightAI, whose VoxelBox neuroimaging software is deployed across dozens of Indian hospitals, and NexStem (now Anthriq), building EEG-based BCI hardware.

From quantified self to clinical

The bet across the sector is that brain wearables become a category the way fitness trackers did, with a clinical wing for the mental-health conditions where India's treatment gap is enormous. The risks are equally clear. Consumer neurotech has a long history of outrunning its evidence, efficacy claims for stimulation and biofeedback devices invite scrutiny, and several of the bolder marketing claims in this wave rest on single sources. Regulatory and clinical validation, not funding announcements, will decide which of these companies endures.

Still, the strategic shape is interesting. While India's universities and national labs, IISc, the IITs, NIMHANS, work on the invasive, deep-science future of neurotechnology, its startups are building the non-invasive, consumer-facing present. A field that barely registered a couple of years ago now has both a research frontier and a funded commercial layer, which is roughly how durable deep-tech industries begin.